Drug Search Results
More Filters [+]

Tisagenlecleucel

Alternative Names: tisagenlecleucel, ctl-019, ctl019, ctl 019, Kymriah
Latest Update: 2024-07-05
Latest Update Note: News Article

Product Description

a CD19 CAR T-cell therapy for the treatment of patients with relapsed/refractory large B cell lymphoma (r/r LBCL). (Sourced from: http://neoimmunetech.com/news/page01_view.html?number=55)

Mechanisms of Action: CAR-T,CD19

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tisagenlecleucel

Countries in Clinic: Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Netherlands, Norway, Poland, Romania, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States

Active Clinical Trial Count: 32

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|B-Cell Leukemia|B-Cell Marginal Zone Lymphoma|Composite Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Inflammation|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Lymphoma

Phase 2: Leukemia|Mantle-Cell Lymphoma

Phase 1: Primary Central Nervous System Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CCTL019E2301

P3

Recruiting

Follicular Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

2031-02-20

CCTL019G2201J

P2

Recruiting

Acute Lymphoid Leukemia|B-Cell Leukemia

2028-08-30

LEDA

P3

Recruiting

Follicular Lymphoma

2028-07-24

CASSIOPEIA

P2

Recruiting

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell

2027-10-19

57%

Recent News Events